<DOC>
	<DOCNO>NCT01601808</DOCNO>
	<brief_summary>ViP double blind clinical trial compare gemcitabine vandetanib chemotherapy gemcitabine alone patient locally advance metastatic pancreatic carcinoma .</brief_summary>
	<brief_title>Clinical Trial Comparing Gemcitabine Vandetanib Therapy With Gemcitabine Alone Pancreatic Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Age ≥ 18 year . Histologically cytologically proven pancreatic ductal adenocarcinoma undifferentiated carcinoma pancreas . Locally advanced metastatic disease preclude curative surgical resection definitive locally direct therapy chemo radiation . Patients relapse follow previously resect Pancreatic Cancer include . Contrast enhance computerise tomography ( CT ) scan thorax , abdomen pelvis within 28 day prior commence treatment . Unidimensionally measurable disease show CT scan , accordance RECIST guideline ( version 1.1 ) ECOG performance status 0 , 1 2 investigator feel treatment combination chemotherapy . Platelets ≥100 x 109/l ; WBC ≥ 3 x 109/l ; neutrophil ≥ 1.5 x 109/l entry . Documented Life expectancy &gt; 3 month . Informed write consent Laboratory result : Serum bilirubin ≥ 1.5x upper limit reference range ( ULRR ) . Haemoglobin &lt; 10G/dl Creatinine clearance &lt; 30 mL/minute ( calculate CockcroftGault formula ) ** . Patients creatinine clearance ≥30mL/minute &lt; 50mL/minute begin vandetanib reduce dose 200mg . Potassium , ≤4.0 mmol/L despite supplementation ; &gt; 5.5 mmol/L Magnesium normal range despite supplementation , &gt; 1.23 mmol/L Serum calcium &gt; 2.9 mmol/L . In case serum calcium normal range substitute value calcium adjust albumin , normal range despite supplementation patient exclude . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) alkaline phosphatase ( ALP ) &gt; 2.5 x ULRR &gt; 5x ULRR judge investigator relate liver metastasis . Medical psychiatric condition compromise informed consent . Intracerebral metastasis meningeal carcinomatosis . Major surgery within 4 week incompletely heal surgical incision start study therapy . Evidence severe uncontrolled systemic disease concurrent condition Clinically significant cardiovascular eventclassification heart disease ≥2 within 3 month entry ; presence cardiac disease , opinion Investigator , increase risk ventricular arrhythmia . History arrhythmia symptomatic require treatment ( CTCAE grade 3 ) asymptomatic sustain ventricular tachycardia . Atrial fibrillation , control medication exclude . QTc prolongation medication require discontinuation medication . Congenital long QT syndrome 1st degree relative unexplained sudden death 40 year age . Presence leave bundle branch block ( LBBB ) . QTc Bazett 's correction unmeasurable ≥ 480 msec screen ECG . Patients receive drug risk induce TorsadesdePointes exclude QTc ≥ 460 msec . Any concurrent medication know risk induce TorsadesdePointes , investigator 's opinion discontinue , allow . Concomitant medication potent inducer . Hypertension control medical therapy . Currently active diarrhoea . Malabsorption syndrome . Pregnancy breast feed . Previous chemotherapy locally advance metastatic disease . Adjuvant chemotherapy resect pancreatic cancer permit provided chemotherapy complete &gt; 12 month previously . Radiotherapy within last 4 week prior start study treatment . Concurrent malignancy invasive cancer diagnose within past 5 year . Chemotherapy direct tumour apart describe protocol . All men woman reproductive potential , unless use least two contraceptive precaution , one must condom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>